Research location
Marlton
New Jersey, United States
Advertisement
Research activity in Marlton
New Jersey, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 234 trials and 236 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Marlton
234 linked trials · page 1 of 5A Study of LTX-001 In Adult Participants With Acute Exacerbation of SchizophreniaNCT07734493 · 2026-08-03 · 1 site observation
RECRUITING
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderNCT07573176 · 2026-04-30 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 · 2026-04-23 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
A Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877 · 2026-01-20 · 1 site observation
RECRUITING
A Study to Evaluate the Effectiveness of DT-101 in Patients With DepressionNCT07300969 · 2025-12-16 · 1 site observation
RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818 · 2025-12-16 · 1 site observation
RECRUITING
Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart FailureNCT07209098 · 2025-11-18 · 1 site observation
RECRUITING
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant ResponseNCT07284667 · 2025-11-14 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTNCT07061288 · 2025-09-03 · 1 site observation
RECRUITING
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With SchizophreniaNCT07191483 · 2025-08-27 · 1 site observation
RECRUITING
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaNCT07145918 · 2025-08-04 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation
RECRUITING
Randomized Withdrawal Study in Patients With SchizophreniaNCT06961968 · 2025-05-14 · 1 site observation
RECRUITING
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT06963034 · 2025-05-08 · 1 site observation
RECRUITING
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)NCT06657768 · 2024-10-29 · 1 site observation
RECRUITING
Global Paradise System US Post Approval StudyNCT06297291 · 2024-06-28 · 1 site observation
RECRUITING
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsNCT06112418 · 2024-03-06 · 1 site observation
RECRUITING
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation
RECRUITING
Left vs Left Randomized Clinical TrialNCT05650658 · 2023-09-13 · 1 site observation
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)NCT07388667 · 2026-03-04 · 1 site observation
COMPLETED
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · 2026-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or ObesityNCT07311850 · 2025-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate Efficacy and Safety of Ropanicant in MDD PatientsNCT06836063 · 2025-07-15 · 1 site observation
COMPLETED
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · 2025-06-27 · 1 site observation
COMPLETED
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
VK2735 for Weight Management Phase 3NCT07104500 · 2025-06-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or OverweightNCT06973720 · 2025-04-07 · 1 site observation
ACTIVE_NOT_RECRUITING
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With SchizophreniaNCT06924255 · 2025-04-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DMNCT06897202 · 2025-03-14 · 1 site observation
COMPLETED
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild AsthmaNCT06702462 · 2025-03-11 · 1 site observation
COMPLETED
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMNCT06845202 · 2025-03-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaNCT06572449 · 2024-10-28 · 1 site observation
COMPLETED
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective DisorderNCT06627413 · 2024-08-23 · 1 site observation
COMPLETED
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsNCT06494397 · 2024-07-11 · 1 site observation
COMPLETED
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.NCT06429722 · 2024-05-13 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityNCT06373146 · 2024-04-24 · 1 site observation
COMPLETED
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective DisorderNCT06319170 · 2024-03-28 · 1 site observation
COMPLETED
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineNCT06280235 · 2024-03-27 · 1 site observation
COMPLETED
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT06254612 · 2024-03-25 · 1 site observation
COMPLETED
PD, PK, and Safety of ALTO-203 in Patients With MDDNCT06391593 · 2024-03-25 · 1 site observation
COMPLETED
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With SchizophreniaNCT06315283 · 2024-03-20 · 1 site observation
COMPLETED
A Study of ANAVEX3-71 in Adults With SchizophreniaNCT06245213 · 2024-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNCT06107803 · 2023-10-13 · 1 site observation
COMPLETED
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)NCT05953740 · 2023-09-15 · 1 site observation
COMPLETED
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)NCT05893862 · 2023-06-26 · 1 site observation
COMPLETED
Pathway for Produce Prescriptions in Diabetes ManagementNCT06058338 · 2023-05-31 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.